MRNA vs RPRX
Moderna and Royalty Pharma plc, both Healthcare
Royalty Pharma plc is the larger company at $31B against $25B. Over the past year MRNA returned +93% against +59% for RPRX. The RyuScore puts RPRX ahead, 52 against 48 out of 100.
| Figure | MRNA | RPRX |
|---|---|---|
| Last close | $62.96 | $56.90 |
| Market cap | $25B | $31B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 30.3 |
| 1-year return | +93% | +59% |
| 5-year return | -81% | +61% |
| RyuScoresector-relative, 1–10 | 48/100 | 52/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.